An expert Q&A with Gregory A. Morris of Honigman Miller Schwartz and Cohn LLP on Orange Book-listed patent challenges before the Patent Trial and Appeal Board (PTAB) under the Leahy-Smith America Invents Act (AIA). The Q&A discusses common scenarios and types of challenges brought by Abbreviated New Drug Application (ANDA) filers in conjunction with Hatch-Waxman litigation, how branded pharmaceutical companies have responded to these challenges and challenges brought by hedge fund companies, and best practices for these proceedings.